000148860 001__ 148860
000148860 005__ 20240229120020.0
000148860 0247_ $$2doi$$a10.1088/1361-6560/ab3841
000148860 0247_ $$2pmid$$apmid:31374558
000148860 0247_ $$2ISSN$$a0031-9155
000148860 0247_ $$2ISSN$$a1361-6560
000148860 0247_ $$2altmetric$$aaltmetric:72944750
000148860 037__ $$aDKFZ-2020-00052
000148860 041__ $$aeng
000148860 082__ $$a530
000148860 1001_ $$aEulitz, J.$$b0
000148860 245__ $$aA Monte Carlo based radiation response modelling framework to assess variability of clinical RBE in proton therapy.
000148860 260__ $$aBristol$$bIOP Publ.$$c2019
000148860 3367_ $$2DRIVER$$aarticle
000148860 3367_ $$2DataCite$$aOutput Types/Journal article
000148860 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577972271_14110
000148860 3367_ $$2BibTeX$$aARTICLE
000148860 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148860 3367_ $$00$$2EndNote$$aJournal Article
000148860 520__ $$aThe clinical implementation of a variable relative biological effectiveness (RBE) in proton therapy is currently controversially discussed. Initial clinical evidence indicates a variable proton RBE, which needs to be verified. In this study, a radiation response modelling framework for assessing clinical RBE variability is established. It was applied to four selected glioma patients (grade III) treated with adjuvant radio(chemo)therapy and who developed late morphological image changes on T1-weighted contrast-enhanced (T1w-CE) magnetic resonance (MR) images within approximately two years of recurrence-free follow-up. The image changes were correlated voxelwise with dose and linear energy transfer (LET) values using univariable and multivariable logistic regression analysis. The regression models were evaluated by the area-under-the-curve (AUC) method performing a leave-one-out cross validation. The tolerance dose TD50 at which 50% of patient voxels experienced toxicity was interpolated from the models. A Monte Carlo (MC) model was developed to simulate dose and LET distributions, which includes variance reduction (VR) techniques to decrease computation time. Its reliability and accuracy were evaluated based on dose calculations of the clinical treatment planning system (TPS) as well as absolute dose measurements performed in the patient specific quality assurance. Morphological image changes were related to a combination of dose and LET. The multivariable models revealed cross-validated AUC values of up to 0.88. The interpolated TD50 curves decreased with increasing LET indicating an increase in biological effectiveness. The MC model reliably predicted average TPS dose within the clinical target volume as well as absolute water phantom dose measurements within 2% accuracy using dedicated VR settings. The observed correlation of dose and LET with late brain tissue damage suggests considering RBE variability for predicting chronic radiation-induced brain toxicities. The MC model simulates radiation fields in patients precisely and time-efficiently. Hence, this study encourages and enables in-depth patient evaluation to assess the variability of clinical proton RBE.
000148860 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000148860 588__ $$aDataset connected to CrossRef, PubMed,
000148860 7001_ $$aLutz, B.$$b1
000148860 7001_ $$aWohlfahrt, P.$$b2
000148860 7001_ $$aDutz, A.$$b3
000148860 7001_ $$0P:(DE-HGF)0$$aEnghardt, W.$$b4
000148860 7001_ $$0P:(DE-HGF)0$$aKarpowitz, C.$$b5
000148860 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, M.$$b6$$udkfz
000148860 7001_ $$0P:(DE-HGF)0$$aTroost, E. G. C.$$b7
000148860 7001_ $$aLühr, A.$$b8
000148860 773__ $$0PERI:(DE-600)1473501-5$$a10.1088/1361-6560/ab3841$$gVol. 64, no. 22, p. 225020 -$$n22$$p225020 $$tPhysics in medicine and biology$$v64$$x1361-6560$$y2019
000148860 909CO $$ooai:inrepo02.dkfz.de:148860$$pVDB
000148860 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000148860 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000148860 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000148860 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000148860 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000148860 9141_ $$y2019
000148860 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000148860 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000148860 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHYS MED BIOL : 2017
000148860 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148860 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148860 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000148860 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000148860 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148860 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000148860 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148860 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148860 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000148860 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000148860 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000148860 9201_ $$0I:(DE-He78)L301-20160331$$kL301$$lDKTK Dresden$$x0
000148860 980__ $$ajournal
000148860 980__ $$aVDB
000148860 980__ $$aI:(DE-He78)L301-20160331
000148860 980__ $$aUNRESTRICTED